JPMorgan Chase & Co. Acquires 772,228 Shares of Vistagen Therapeutics, Inc. (NASDAQ:VTGN)

JPMorgan Chase & Co. increased its holdings in Vistagen Therapeutics, Inc. (NASDAQ:VTGN - Free Report) by 4,826,425.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 772,244 shares of the company's stock after purchasing an additional 772,228 shares during the quarter. JPMorgan Chase & Co. owned approximately 2.77% of Vistagen Therapeutics worth $2,278,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Virtu Financial LLC lifted its holdings in Vistagen Therapeutics by 30.5% during the 3rd quarter. Virtu Financial LLC now owns 20,210 shares of the company's stock worth $61,000 after buying an additional 4,722 shares during the period. R Squared Ltd acquired a new position in shares of Vistagen Therapeutics in the fourth quarter worth approximately $25,000. Jane Street Group LLC bought a new stake in Vistagen Therapeutics in the third quarter valued at approximately $59,000. HighTower Advisors LLC acquired a new stake in Vistagen Therapeutics during the 3rd quarter valued at approximately $64,000. Finally, Prosperity Wealth Management Inc. bought a new position in Vistagen Therapeutics during the 4th quarter worth approximately $86,000. 78.39% of the stock is currently owned by institutional investors and hedge funds.

Vistagen Therapeutics Stock Performance

Shares of NASDAQ VTGN traded down $0.12 during midday trading on Friday, reaching $2.22. The stock had a trading volume of 73,220 shares, compared to its average volume of 172,384. Vistagen Therapeutics, Inc. has a twelve month low of $1.90 and a twelve month high of $4.96. The company's 50 day moving average price is $2.48 and its 200 day moving average price is $2.72. The firm has a market cap of $64.07 million, a price-to-earnings ratio of -1.50 and a beta of 0.56.

Vistagen Therapeutics (NASDAQ:VTGN - Get Free Report) last issued its quarterly earnings results on Thursday, February 13th. The company reported ($0.46) EPS for the quarter, beating analysts' consensus estimates of ($0.48) by $0.02. Vistagen Therapeutics had a negative net margin of 6,777.08% and a negative return on equity of 48.12%. The business had revenue of $230 billion for the quarter, compared to analysts' expectations of $0.18 million. Equities analysts forecast that Vistagen Therapeutics, Inc. will post -1.77 earnings per share for the current fiscal year.

Vistagen Therapeutics Profile

Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.